Englitazone sodium is an antidiabetic agent. Englitazone sodium is also a novel blocker of NSCa and KATP channels. The inhibition of KATP channels occurs following procedures that dissociate sulphonylurea receptor coupling to the channel. References: McKay NG, Kinsella JM, Campbell CM, Ashford ML. Sensitivity of Kir6.2-SUR1 currents, in the absence and presence of sodium azide, to the K(ATP) channel inhibitors, ciclazindol and englitazone. Br J Pharmacol. 2000 Jun;130(4):857-66. PubMed PMID: 10864893; PubMed Central PMCID: PMC1572145.

纯度：≥98%

CAS：109229-57-4